trending Market Intelligence /marketintelligence/en/news-insights/trending/IZFb4xWPjMkofQ4w19Z4iw2 content esgSubNav
In This List

Roche hemophilia drug sees positive phase 3 study results

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Roche hemophilia drug sees positive phase 3 study results

Roche Holding Ltd.'s hemophilia A drug candidate met its primary- and- secondary endpoints in a phase 3 study.

ACE910, or emicizumab, showed a significant reduction in the number of bleeds over time in 12-year-old patients and older when compared to no prophylactic treatment.

The company also said it had resolved the thrombosis concerns raised earlier during the trial.